These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33844184)

  • 1. Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease.
    Rossi F; Svarstad E; Elsaid H; Binaggia A; Roggero L; Auricchio S; Marti HP; Pieruzzi F
    High Blood Press Cardiovasc Prev; 2021 May; 28(3):309-319. PubMed ID: 33844184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Pressure Control in Hypertensive Patients, Cardiovascular Risk Profile and the Prevalence of Masked Uncontrolled Hypertension (MUCH).
    Naser N; Dzubur A; Durak A; Kulic M; Naser N
    Med Arch; 2016 Jul; 70(4):274-279. PubMed ID: 27703288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Pressure Variability in Fabry Disease Patients.
    Dincer MT; Ozcan SG; Ikitimur B; Kiykim E; Bakir A; Trabulus S; Seyahi N
    Nephron; 2022; 146(4):343-350. PubMed ID: 34933310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals (summary). Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM)].
    Hermida RC; Smolensky MH; Ayala DE; Portaluppi F; Crespo JJ; Fabbian F; Haus E; Manfredini R; Mojón A; Moyá A; Piñeiro L; Ríos MT; Otero A; Balan H; Fernández JR
    Clin Investig Arterioscler; 2013; 25(2):74-82. PubMed ID: 23849214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prehypertension and masked hypertension rate among clinically normotensive patients.
    Unsal S; Ozkara A; Albayrak T; Ozturk Y; Beysel S; Kucukler FK
    Clin Exp Hypertens; 2016; 38(2):218-24. PubMed ID: 26818410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes.
    Ayala DE; Moyá A; Crespo JJ; Castiñeira C; Domínguez-Sardiña M; Gomara S; Sineiro E; Mojón A; Fontao MJ; Hermida RC;
    Chronobiol Int; 2013 Mar; 30(1-2):99-115. PubMed ID: 23098178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masked hypertension and target organ damage in treated hypertensive patients.
    Tomiyama M; Horio T; Yoshii M; Takiuchi S; Kamide K; Nakamura S; Yoshihara F; Nakahama H; Inenaga T; Kawano Y
    Am J Hypertens; 2006 Sep; 19(9):880-6. PubMed ID: 16942927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension.
    Stergiou GS; Argyraki KK; Moyssakis I; Mastorantonakis SE; Achimastos AD; Karamanos VG; Roussias LG
    Am J Hypertens; 2007 Jun; 20(6):616-21. PubMed ID: 17531917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of uncontrolled hypertension in patients with Fabry disease.
    Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
    Am J Hypertens; 2006 Aug; 19(8):782-7. PubMed ID: 16876675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure.
    Hoshide S; Ishikawa J; Eguchi K; Ojima T; Shimada K; Kario K
    Hypertens Res; 2007 Feb; 30(2):143-9. PubMed ID: 17460384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Performance of Office versus Ambulatory Blood Pressure in Kidney Transplant Recipients.
    Korogiannou M; Sarafidis P; Theodorakopoulou MP; Alexandrou ME; Xagas E; Boletis IN; Marinaki S
    Am J Nephrol; 2021; 52(7):548-558. PubMed ID: 34311458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome.
    Stergiou GS; Asayama K; Thijs L; Kollias A; Niiranen TJ; Hozawa A; Boggia J; Johansson JK; Ohkubo T; Tsuji I; Jula AM; Imai Y; Staessen JA;
    Hypertension; 2014 Apr; 63(4):675-82. PubMed ID: 24420553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agreement Between Ambulatory and Home Blood Pressure Monitoring in Detecting Nighttime Hypertension and Nondipping Patterns in the General Population.
    Lindroos AS; Kantola I; Salomaa V; Juhanoja EP; Sivén SS; Jousilahti P; Jula AM; Niiranen TJ
    Am J Hypertens; 2019 Jul; 32(8):734-741. PubMed ID: 31028705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masked hypertension defined by ambulatory blood pressure monitoring is associated with an increased serum glucose level and urinary albumin-creatinine ratio.
    Ishikawa J; Hoshide S; Eguchi K; Schwartz JE; Pickering TG; Shimada K; Kario K
    J Clin Hypertens (Greenwich); 2010 Aug; 12(8):578-87. PubMed ID: 20695934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Peripheral-Central Blood Pressure and Cardiac-Renal Damage in Kidney Transplant Recipients.
    Firat A; Kaya B; Balal M; Paydas S; Akilli R
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):188-194. PubMed ID: 30777552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.
    Scheppach JB; Raff U; Toncar S; Ritter C; Klink T; Störk S; Wanner C; Schlieper G; Saritas T; Reinartz SD; Floege J; Janka R; Uder M; Schmieder RE; Eckardt KU; Schneider MP
    Hypertension; 2018 Oct; 72(4):929-936. PubMed ID: 30354716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.